Maria Beconi
Publications by Year
Research Areas
Diabetes Treatment and Management, Peptidase Inhibition and Analysis, Neuropeptides and Animal Physiology, Genetic Neurodegenerative Diseases, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2004)814 cited
- → Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes(2005)490 cited
- → Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease(2013)147 cited
- → (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2006)121 cited
- → Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors(2008)106 cited
- → Pharmacokinetics of memantine in rats and mice(2011)85 cited
- → Use of on‐line hydrogen/deuterium exchange to facilitate metabolite identification(2001)75 cited
- → Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease(2012)69 cited
- → A semi-automated method for measuring the potential for protein covalent binding in drug discovery(2005)68 cited
- → Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease(2015)61 cited